MEI Pharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 77   

Articles published

MEIP 1.36 +0.02 (1.49%)
price chart
MEI Pharma, Inc. (NASDAQ:MEIP) Moderate Sell Ratings At 0
MEI Pharma, Inc. (NASDAQ:MEIP) strong sell score is 0 while buy rating count is 1. Moderate sell ratings are 0 while moderate buy calls are 0. Hold ratings count is 0. As many as 0 brokerages initiated coverage on MEI Pharma, Inc. (NASDAQ:MEIP) while 1 ...
MEI Pharma Inc (MEIP) Poised To Move Higher; Here's Why
Having seen the updated Pracinostat overall survival data in elderly Acute Myeloid Leukemia (AML) from MEI Pharma (NASDAQ:MEIP) presented at the recent Needham Healthcare Conference, I believe this is another opportunity to buy a severely ...
Can MEI Pharma Survive?
MEI Pharma Inc. (NASDAQ: MEIP) announced results from one of its studies, and the stock cratered as a result. Now analysts are making their calls on where the stock looks to go from here.
Cantor Remains Positive on MEI Pharma Inc Following Failed Phase II Study ...  Smarter Analyst
Cantor Is Slashing Its MEI Pharma Price Target  Benzinga
MEI Pharma, Inc Pipeline Review, Market Share, Strategy, Size and Forecast ...
market-research-store1161 “MEI Pharma, Inc Global 2015 Clinical Trials Review, H2” provides an detailed overview of MEI Pharma, Inc scenario. Report includes top line data relating on MEI Pharma, Inc Global clinical trials scenario. This report on MEI ...
Strong Buy Calls Count For MEI Pharma, Inc. (NASDAQ:MEIP) At 0
In the same period, MEI Pharma, Inc. (NASDAQ:MEIP) posted 3 hold calls. The buy recommendations were 0 and sell calls count was 0. Analyst score was 3. A quarter ago, MEI Pharma, Inc. (NASDAQ:MEIP) posted mean score of 3 and 0 were Strong Sell ...
MEI Pharma Should Be Bought Ahead Of ASH Conference
Pracinostat Phase 2 data presented at ASH will illustrate survival benefit in AML and favorable outcomes in MDS patients. MEI Pharma also has two other promising clinical stage drugs in the pipeline with PWT143, (PI3K Delta Inhibitor) and a novel ...
MEI Pharma, Inc. (NASDAQ:MEIP) Short Ratio At 4.28
The technical analysis of MEI Pharma, Inc. (NASDAQ:MEIP) highlights the stock is $-0.12 points away -8.69% from 50-day MA of $1.39.
MEI Pharma, Inc. (NASDAQ:MEIP) Has Been Assigned An Impact Score Of 50  Markets Daily
Analyst Views For The Week Ahead: MEI Pharma, Inc. (MEIP)  Fiscal Standard
Latest Analyst Reports On MEI Pharma, Inc.
Recently stock market analysts have updated their consensus ratings on shares of MEI Pharma, Inc. (MEIP). Most recent broker ratings.
Short Interest in MEI Pharma Inc (MEIP) Declines By 21.2%  The Cerbat Gem
Stock Update (NASDAQ:MEIP): MEI Pharma Inc Highlights New Data from Phase II ...
MEI Pharma Inc (NASDAQ:MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced the publication of new data from the Company's Phase II clinical studies of the investigational drug Pracinostat in ...
MEI Pharma Highlights New Data from Phase II Clinical Studies of Pracinostat ...  PR Newswire (press release)
Share Volatility Check for: MEI Pharma, Inc. (NASDAQ:MEIP)
MEI Pharma, Inc. (NASDAQ:MEIP)'s shares are highly volatile in today's session as the stock moved -1.49%, clocking in at $1.32 with a recent bid.